| Ytd | -82.88% | |
| 1y | -94.25% |
| Open | 0.79 | Prev Close | 0.77 | Low | 0.77 | High | 0.79 | Mkt Cap | 1.62M |
| Vol | 7.36K | Avg Vol | 214.44K | EPS | -2.56 | P/E | -0.30 | Forward P/E | -5.83 |
| Beta | 1.14 | Short Ratio | 13.56 | Inst. Own | 15.83% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 0.94 | 200-d Avg | 4.44 | 1yr Est | 12.75 |
FBLG News
Microbiologist, Retired NASA Astronaut, and Founding Director of the University of Pittsburgh Trived
Company expects existing supply will suffice to complete clinical trial and lead to cost savingsHOUS
Company expects existing supply will suffice to complete clinical trial and lead to cost savings HOU
HOUSTON, June 30, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a cli
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds up
FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics" or the "Company"), a clinical-
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds up
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology compa
Allowed claims directly support the Company's ongoing Phase 1/2 clinical trial of CYWC628 in patient
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology compa
HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a
HOUSTON, June 03, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a
FibroBiologics Inc. (NASDAQ: FBLG) reports enrolling first patients in its Phase 1/2 trial for CYWC6
FibroBiologics Inc. (NASDAQ: FBLG) reports enrolling first patients in its Phase 1/2 trial for CYWC6
Psoriasis is a chronic inflammatory skin disease driven by dysregulated innate and adaptive immunity
In animal studies, human dermal fibroblast spheroids reduce disease severity, prevent relapse, and s
The application covers oral delivery systems designed to protect fibroblast-based therapeutics throu
HOUSTON, May 18, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology compan
Will Apply Existing Preclinical Findings in Reducing Severe Immune-Mediated Lung Failure to Potentia
HOUSTON, May 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a
HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a
HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a
FibroBiologics releases CYWC628 batch for DFU trial, clears cGMP checks, prepares enrollment; interi
On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulc
HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”),
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology compan
HOUSTON, April 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"),
HC Wainwright & Co. analyst Matthew Caufield maintains FibroBiologics (NASDAQ:FBLG) with a Bu
Ordinary shares will continue to trade on the Nasdaq Capital Market, and the Company's listing o
https://data.epo.org/publication-server/publications/pdf?path=2026/16/DOC/EPNWB1/EP19795797NWB1/EP19
Preclinical models demonstrate potential to restore thymic function lost with aging reducing suscept
Shares of nCino Inc (NASDAQ: NCNO) jumped 18% in pre-market trading after reporting strong Q4 result
FibroBiologics completes first CYWC628 batch for diabetic foot ulcers trials, advances pipeline amid
The reverse stock split is expected to become effective at 12:01 a.m. Eastern Time on March 30, 2026
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology compa
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology compan
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-
HC Wainwright & Co. analyst Matthew Caufield maintains FibroBiologics (NASDAQ:FBLG) with a Bu
D. Boral Capital analyst Jason Kolbert maintains FibroBiologics (NASDAQ:FBLG) with a Buy and lowe
FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) reported quarterly losses of $(0.03) per share whi
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-
